2017
DOI: 10.3389/fimmu.2017.00258
|View full text |Cite
|
Sign up to set email alerts
|

Type I and III Interferon in the Gut: Tight Balance between Host Protection and Immunopathology

Abstract: The intestinal mucosa forms an active interface to the outside word, facilitating nutrient and water uptake and at the same time acts as a barrier toward the highly colonized intestinal lumen. A tight balance of the mucosal immune system is essential to tolerate harmless antigens derived from food or commensals and to effectively defend against potentially dangerous pathogens. Interferons (IFN) provide a first line of host defense when cells detect an invading organism. Whereas type I IFN were discovered almos… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
44
1
4

Year Published

2017
2017
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 56 publications
(50 citation statements)
references
References 140 publications
(244 reference statements)
1
44
1
4
Order By: Relevance
“…Therefore, it is possible that type III IFN may be the predominant IFN to mediate antiviral effects in the liver, while type I IFN may play an important role in enterocytes, the initial site of HEV replication. Interestingly, type III IFN is known to contribute to antiviral responses at the intestinal mucosal surface (30,31); however, in this study, we found that HEV RNA PAMPs induced higher type I IFN mRNA levels than type III IFN levels in enterocytes. Therefore, more in-depth in vivo studies are warranted to more definitively delineate the role of type I and type III IFNs at various target organs during HEV infection.…”
Section: Discussioncontrasting
confidence: 77%
“…Therefore, it is possible that type III IFN may be the predominant IFN to mediate antiviral effects in the liver, while type I IFN may play an important role in enterocytes, the initial site of HEV replication. Interestingly, type III IFN is known to contribute to antiviral responses at the intestinal mucosal surface (30,31); however, in this study, we found that HEV RNA PAMPs induced higher type I IFN mRNA levels than type III IFN levels in enterocytes. Therefore, more in-depth in vivo studies are warranted to more definitively delineate the role of type I and type III IFNs at various target organs during HEV infection.…”
Section: Discussioncontrasting
confidence: 77%
“…While IFNLR1 expression has also been reported on NK cells, T cells, B cells, and pDCs (26)(27)(28)(29)(30), no role has been found for these cells in IFN-λ-mediated antiviral responses. Type I IFNs, on the other hand, are critical for preventing a virus from moving past this initial epithelial barrier into systemic tissues (24,25,31). The host may benefit by inducing specific and local barrier defenses at a site commonly exposed to pathogens via IFN-λ signaling, and thus avoid potentially detrimental systemic inflammatory responses by type I IFNs.…”
Section: Figure 1 | Effects Of Interferon-lambda (Ifn-λ) On Viruses Imentioning
confidence: 99%
“…Type I IFNs signal through the interferon alpha receptor (IFNAR) to activate the Janus kinase and signal transducer and activator of transcription (JAK-STAT) pathway to induce ISG transcription (9). Type III IFN, also known as interferon lambda (IFN-) or interleukin 28 (IL-28)/IL-29, binds to an IL-28 receptor alpha (IL-28R␣)/IL-10R␤ heterodimeric receptor (IFNLR) to activate the JAK-STAT pathway and plays an important role in antiviral immunity at mucosal surfaces, including the lung and gastrointestinal tract (10)(11)(12). Investigation of hostvirus interactions has uncovered critical roles for both type I and type III IFNs in the regulation of acute and persistent strains of MNoV (5,7,13,14).…”
mentioning
confidence: 99%